89Zr-DFO-AP-101
Phase 1Active 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Amyotrophic Lateral Sclerosis
Conditions
Amyotrophic Lateral Sclerosis
Trial Timeline
Nov 23, 2023 → Mar 31, 2025
NCT ID
NCT05974579About 89Zr-DFO-AP-101
89Zr-DFO-AP-101 is a phase 1 stage product being developed by Eli Lilly for Amyotrophic Lateral Sclerosis. The current trial status is active. This product is registered under clinical trial identifier NCT05974579. Target conditions include Amyotrophic Lateral Sclerosis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05974579 | Phase 1 | Active |
Competing Products
20 competing products in Amyotrophic Lateral Sclerosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AL001 + Placebo | Alector | Phase 2 | 44 |
| Reldesemtiv + Placebo | Astellas Pharma | Phase 2 | 52 |
| Perampanel + Placebo Oral Tablet | Eisai | Pre-clinical | 23 |
| E0302 (mecobalamin) | Eisai | Phase 2/3 | 65 |
| E0302 (mecobalamin) + E0302 (mecobalamin) + Placebo | Eisai | Phase 2/3 | 65 |
| methylcobalamin + saline solution | Eisai | Phase 3 | 77 |
| ONO-2506PO | Ono Pharmaceutical | Phase 2 | 52 |
| ONO-2506PO + ONO-2506PO | Ono Pharmaceutical | Phase 2 | 52 |
| ZYIL1 capsules 25 mg and 50 mg Placebo + ZYIL1 capsules 50 mg and 25 mg Placebo + ZYIL1 capsules 25 mg and ZYIL1 capsules 50 mg + Matching placebo 25 mg and Matching placebo 50 mg | Zydus Lifesciences | Phase 2 | 52 |
| LY4256984 + Placebo | Eli Lilly | Phase 1 | 33 |
| TCH346 | Novartis | Phase 2 | 52 |
| VHB937 | Novartis | Phase 2 | 52 |
| TCH346 | Novartis | Phase 2 | 52 |
| TCH346 | Novartis | Phase 2 | 52 |
| BLZ945 | Novartis | Phase 2 | 52 |
| TRO19622 | Roche | Phase 2/3 | 65 |
| Olesoxime + Placebo Comparator + Riluzole | Roche | Phase 3 | 77 |
| Bosutinib (Phase 1 part) + Bosutinib (Phase 2 part) | Pfizer | Phase 1/2 | 40 |
| Celecoxib + Creatine + Minocycline | Pfizer | Phase 2 | 51 |
| DNL747 + Placebo | Sanofi | Phase 1 | 32 |